PP
FLGT icon

Paloma Partners’s Fulgent Genetics FLGT Stock Holding History

Paloma Partners’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,300
Closed -$1.14M – 1919
2021
Q4 		$1.14M Buy
+11,300
New +$993K 0.02% 642
2020
Q2 		– Sell
-11,245
Closed -$121K – 2123
2020
Q1 		$121K Buy
+11,245
New +$157K 0.01% 1013

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Paloma Partners's FLGT Position: Q1 2022 in Review

Paloma Partners sold out of Fulgent Genetics (FLGT) in Q1 2022, closing a stake of 11,300 shares — an estimated $1.14M sold.

Paloma Partners first reported a position in FLGT in Q1 2020 and held it in 2 quarters. The position peaked at $1.14M in Q4 2021. 275 funds tracked by Wall St. Rank hold FLGT as of Q1 2022.

  • Paloma Partners reported no remaining Fulgent Genetics position as of Q1 2022 after selling out during the quarter.
  • Paloma Partners sold 11,300 Fulgent Genetics shares in Q1 2022, an estimated $1.14M.
  • Paloma Partners first reported a position in Fulgent Genetics in Q1 2020 and held it in 2 quarters.
  • Paloma Partners's Fulgent Genetics position peaked at $1.14M in Q4 2021.
  • 275 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2022.

Based on Paloma Partners's 13F filing for Q1 2022, filed 16 May 2022.